OGEN - Oragenics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.4200
+0.0190 (+4.74%)
As of 3:03PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4010
Open0.4010
Bid0.4126 x 800
Ask0.4130 x 1100
Day's Range0.4000 - 0.4200
52 Week Range0.3800 - 6.8000
Volume399,407
Avg. Volume520,565
Market Cap4.972M
Beta1.40
PE Ratio (TTM)N/A
EPS (TTM)-1.5190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)?
    Simply Wall St.23 hours ago

    Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)?

    Oragenics Inc (NYSEMKT:OGEN), a US$5.0m small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronicRead More...

  • Business Wireyesterday

    Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced that Dr. Martin Handfield, the company’s senior vice president of discovery research will present data on its lantibiotics program for the treatment of serious and prevalent infectious diseases at the Boulder Peptide Symposium on Monday, September 24, 2018 at 12:55 PM MT at the St. Julien Hotel and Spa in Boulder, CO.

  • Zacks Small Cap Researchlast month

    OGEN: Positive DSMB Review for Phase 2 Trial of AG013…

    Oragenics, Inc. (OGEN) is currently conducting a Phase 2, double blind, placebo controlled clinical trial of AG013 (NCT03234465). AG013 is an oral mouth rinse composed of a recombinant L. lactis strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. Approximately 160-180 subjects with head and neck cancer receiving chemotherapy will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s chemotherapy plan).

  • Business Wirelast month

    Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential treatment of OM following a positive review by an independent Data Safety Monitoring Board (DSMB). In May 2018, Oragenics reported positive interim safety analysis results based on the first 19 patients, which were evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examination, clinical laboratory assessment and the potential presence of AG013 in blood.

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks

    Stock Research Monitor: OGEN, ONCE, and SBOT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • Zacks Small Cap Research2 months ago

    OGEN: Raises Net Proceeds of $12.3 Million in Underwritten Public Offering

    Oragenics, Inc. (OGEN) is a biopharmaceutical company developing a new treatment for oral mucositis and novel antibiotic therapies for infectious diseases. AG013 is currently being studied in a Phase 2 clinical trial with results expected in mid-2019.

  • Business Wire2 months ago

    Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the “Company”) today announced the closing of an underwritten public offering of units for gross proceeds of approximately $13.8 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering was comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and a seven-year warrant to purchase one share of common stock with an exercise price of $1.00 per share (each, a “Warrant” and collectively, the “Warrants”), and Class B Units, priced at a public offering price of $1.00 per unit, with each unit comprised of one share of series D preferred stock (the “Series D Preferred Stock”), which is convertible into one share of common stock, and a Warrant.

  • Business Wire2 months ago

    Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering

    Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the “Company”) today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is comprised of 2,636,000 Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and a seven-year warrant to purchase one share of common stock at an exercise price of $1.00 per share, and 9,364,000 Class B Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of Series D Preferred stock, having a conversion price of $1.00, and a seven-year warrant to purchase one share of common stock with an exercise price of $1.00 per share.

  • ACCESSWIRE3 months ago

    Free Technical Research on Nektar Therapeutics and Three More Biotech Equities

    On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).

  • Business Wire3 months ago

    Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections

    Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper entitled “OG716: designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections” in PLOS ONE, a peer-reviewed open access scientific journal published by the Public Library of Science. Researchers sought to discover a lead candidate for the treatment of Clostridium difficile (C. difficile) based on a second-generation library of over 300 variants of the lantibiotic Mutacin 1140 (MU1140). MU1140 remains an attractive lantibiotic due to its novel mechanism of action that may limit the development of drug resistance.

  • Zacks Small Cap Research3 months ago

    OGEN: Initiating Coverage of Oragenics, Inc.; Developing a Novel Class of Antibiotics and Treatment for Oral Mucositis

    We are initiating coverage of Oragenics, Inc. (OGEN) with a $7.00 valuation. Oragenics is a biopharmaceutical company developing a new treatment for oral mucositis (OM) and a novel class of antibiotics. AG013 is the company’s lead product for the treatment of OM, a painful inflammation and ulceration of the lining of the mouth, throat, and esophagus that is one of the most common side effects of cancer chemotherapy and radiation treatment.

  • Is Oragenics Inc’s (NYSEMKT:OGEN) CEO Paid At A Competitive Rate?
    Simply Wall St.3 months ago

    Is Oragenics Inc’s (NYSEMKT:OGEN) CEO Paid At A Competitive Rate?

    Alan Joslyn took the reins as CEO of Oragenics Inc’s (AMEX:OGEN) and grew market cap to US$8.52M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Oragenics and Sigma Labs

    NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Oragenics and Sigma Labs were both big winners in the biotech arena on Wednesday. Shares of Oragenics climbed higher after announcing positive results from its interim safety analysis on patients from its Phase 2 clinical trial of AG013. AG013 is a promising product for the prevention of oral mucositis in cancer patients.

  • Business Wire4 months ago

    Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced positive results from its interim safety analysis as requested by FDA on patients from its Phase 2 clinical trial of AG013 for the treatment of OM. The study provides information that, we believe, likely indicates that the overall incidence of severe OM is less than would be anticipated in the general population. Safety was evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examinations, clinical laboratory assessments and the presence of AG013 in whole blood.

  • ACCESSWIRE4 months ago

    Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar

    Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...

  • Business Wire4 months ago

    Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140

    Among other things, the patent covers the unique variants of the lantibiotic 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features as well as the methods of using these compositions to treat and prevent infections, diseases, and colonization by one or more types of bacteria. “In recent years, antibiotic resistant bacteria have been on the rise, affecting millions of people worldwide and resulting in an increasingly large burden on the healthcare system. Lantibiotics serve as an important class of antibiotics with the potential to serve in the treatment of problematic infections caused by Gram-positive bacteria, while also potentially limiting the development of drug resistance,” Alan Joslyn, chief executive officer and president of Oragenics, said.

  • Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?
    Simply Wall St.5 months ago

    Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?

    In this analysis, my focus will be on developing a perspective on Oragenics Inc’s (AMEX:OGEN) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...

  • Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?
    Simply Wall St.5 months ago

    Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?

    For Oragenics Inc’s (AMEX:OGEN) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. OGEN is exposed toRead More...

  • Business Wire5 months ago

    Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering

    Florida-based biopharmaceutical company Oragenics, Inc.  today announced that it has entered into a securities purchase agreement with certain new institutional investors providing for the purchase and sale of 900,000 shares of common stock at a price of $2.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $1.8 million.

  • Business Wire6 months ago

    Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. , a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has completed enrollment of the interim analysis cohort of 20 patients in its Phase 2 clinical trial of AG013 for the treatment of oral mucositis .

  • Business Wire6 months ago

    Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile

    Oragenics, Inc. , a clinical stage biotechnology company, today announced the publication of a research paper entitled “Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection” in the peer reviewed journal, Frontiers in Microbiology, the largest microbiology journal in the world.

  • Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?
    Simply Wall St.6 months ago

    Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?

    After looking at Oragenics Inc’s (AMEX:OGEN) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • ACCESSWIRE6 months ago

    Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Oragenics, Inc. (NYSE American: OGEN) will be presenting at this year's MicroCap Conference on April 9 th and 10 th in New York City. CONFERENCE OVERVIEW AND ...

  • Business Wire7 months ago

    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

    Oragenics, Inc. today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on February 16, 2018 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph....